Answers are grounded in this paper and cite their sources.
OBJECTIVE: To determine the effect of insulinlike growth factor I (IGF-I) in combination with its principal binding protein (IGFBP-3) on the hepatic acute phase response in severely burned children. SUMMARY BACKGROUND DATA: The hepatic acute phase response is a cascade of events initiated to restore homeostasis after trauma. A prolonged response, however, may contribute to multiple organ failure, hypermetabolism, complications, and death. METHODS: Twenty-two children with a mean total body surface area (TBSA) burn of 57 +/- 3% were given a continuous infusion of 1 to 4 mg/kg/day IGF-I/BP-3 for 5 days after wound excision and grafting. Eight children with a TBSA burn of 54 +/- 4% were given saline as controls. Before and 5 days after excision and grafting, blood samples were taken for serum hepatic constitutive protein, acute phase protein, and proinflammatory cytokine analysis. RESULTS: Serum IGF-I levels in burned children given the IGF-I/BP-3 complex increased from 113 +/- 15 to 458 +/- 40 ng/mL and IGFBP-3 levels increased from 1.8 +/- 0.2 to 3.1 +/- 0.3 ng/mL. Levels of serum constitutive hepatic proteins (prealbumin, retinol-binding protein, and transferrin) increased with IGF-I/BP-3, whereas levels of type I acute phase proteins (C-reactive protein, alpha1-acid glycoprotein, and complement C-3) decreased when compared with controls. The complex had no effect on type II acute phase proteins. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) levels decreased with IGF-I/BP-3 compared with controls, with no effect on interleukin-6. CONCLUSION: Severely burned children receiving IGF-I/BP-3 showed a decrease in IL-1beta and TNF-alpha followed by a decrease in type I acute phase proteins that was associated with a concomitant increase in constitutive hepatic proteins. Attenuating the proinflammatory acute phase with IGF-1/BP-3 response may prevent multiple organ failure and improve clinical outcomes after thermal injury without any detectable adverse side effects.
No takes yet. Share an insight, caveat, or question.
Jeschke et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: